Abbott Laboratories $ABT Shares Acquired by Cox Capital Mgt LLC

08 Oct 2026, 00:00 by Kim Johansen · The Markets Daily

Cox Capital Mgt LLC raised its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 72.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,525 shares of the healthcare product maker’s stock after buying an additional 11,971 shares during the quarter. Abbott Laboratories accounts for about 1.6% of Cox Capital Mgt LLC’s investment portfolio, making the stock its 21st largest position. Cox Capital Mgt LLC’s holdings in Abbott Laboratories were worth $2,819,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ABT. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the fourth quarter worth $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories during the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the 4th quarter valued at $26,000. Abound Financial LLC acquired a new stake in Abbott Laboratories in the 4th quarter worth $26,000. Finally, Prudent Man Investment Management Inc. acquired a new stake in Abbott Laboratories in the 4th quarter worth $33,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Price Performance

NYSE ABT traded up $0.54 on Wednesday, reaching $98.70. The company’s stock had a trading volume of 9,392,108 shares, compared to its average volume of 11,346,689. The firm has a market cap of $170.79 billion, a PE ratio of 31.94, a price-to-earnings-growth ratio of 1.86 and a beta of 0.59. The business has a 50-day moving average price of $106.52 and a 200 day moving average price of $98.39. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $135.13. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Barclays initiated coverage with an “overweight” rating and a $120 price target, implying substantial upside from recent levels. The firm’s bullish view reflects growing confidence in Abbott’s medical-device and broader medtech exposure. Stryker, Abbott among overweight ideas as Barclays turns bullish on MedTech
Positive Sentiment: Analyst research highlighted a bullish initiation on Abbott, adding to favorable sentiment around the shares. This Abbott Analyst Begins Coverage On A Bullish Note
Positive Sentiment: Evercore ISI raised its price target to $124 from $120 while maintaining an “outperform” rating, signaling confidence in Abbott’s longer-term earnings potential. Evercore ISI Adjusts Price Target on Abbott Laboratories
Positive Sentiment: Abbott introduced Ensure Max Protein 3-in-1 Muscle Support, combining protein, creatine, and HMB in one product. The launch expands its consumer-health offering and targets growing mainstream wellness demand, though the near-term financial effect is likely limited. Abbott introduces Ensure Max Protein 3-in-1 Muscle Support
Neutral Sentiment: Commentary describes ABT as a potential dividend bargain following its 2026 decline. Abbott has made 411 consecutive quarterly dividend payments since 1924, appealing to income-focused investors, but the company is not currently showing rapid growth trends. Is Abbott Laboratories a Dividend Bargain After Its 2026 Selloff?
Negative Sentiment: Abbott recently declined even as the broader market advanced, indicating continued stock-specific pressure and cautious investor sentiment. The pullback may improve dividend valuation, but it also reflects concerns about growth and near-term momentum. Abbott Stock Drops Despite Market Gains

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ABT shares. Bank of America cut their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. JPMorgan Chase & Co. boosted their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. UBS Group reduced their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Finally, Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a report on Thursday, August 13th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $118.88.

Read Our Latest Report on Abbott Laboratories

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.